Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma

seekingalpha2021-06-18

BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

7fbd9d
2021-06-20
7fbd9d
Ok
Pierroye
2021-06-18
Pierroye
Great. Like and comment pls
LWayne
2021-06-18
LWayne
More pls
LaiSB
2021-06-18
LaiSB
Soon will up
Jack1999
2021-06-18
Jack1999
Pls comment and like
- Ljj96:
  Me too
Mm101
2021-06-18
Mm101
Nice

发表看法

119

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1166489816?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-06-18 17:41","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1166489816","market":"us","top_or_hot":-1,"title":"Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma","media":"seekingalpha","content":"<div>\n<p>BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed ...</p>\n\n<a href=\"https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDosing underway in BioNTech's Phase 2 trial of mrna-based BNT111 in advanced melanoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 17:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed ...</p>\n\n<a href=\"https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"https://seekingalpha.com/news/3707553-dosing-underway-in-biontechs-phase-2-trial-of-mrna-based-bnt111-in-advanced-melanoma","article_id":"1166489816","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166489816","pubTimestamp":1624009298,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTX":"BioNTech SE"},"translate_title":"BionTech的基于mRNA的BNT111治疗晚期黑色素瘤的2期试验正在进行剂量给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":0.9},"content_text":"BioNTech(NASDAQ:BNTX)announcesthat the first patient has been treated in its Phase 2 cancer vaccine trial, evaluating the Company’s BNT111in combination with Libtayo (cemiplimab), being co-developed by Regeneron(NASDAQ:REGN)and Sanofi(NASDAQ:SNY)in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma.\nThe trial is enrolling a total of 120 patients. The primary endpoint is the overall response rate (ORR) of BNT111 in combination with Libtayo.\nSecondary endpoints include ORR in the single agent arms, duration of response, and safety.\nThe first patient has been dosed in the EU. BioNTech retains global commercial rights to BNT111.\nThis Phase 2 clinical trial is based on previous results from the Phase 1 Lipo-MERIT dose escalation trial that demonstrated a favorable safety profile in 89 patients with advanced melanoma.\nThe Company also plans to start randomized Phase 2 trials with mRNA vaccine product candidates in two additional programs in 2021 (FixVac: BNT113 and iNeST: BNT122).\nThe BNT111-01 trial is being conducted in collaboration with Regeneron.\nBioNTech CEO Ugur Sahin warns of possible COVID resurgence from Delta variant","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":165447047,"gmtCreate":1624156026589,"gmtModify":1634010151202,"author":{"id":"3581578814224856","authorId":"3581578814224856","authorIdStr":"3581578814224856","name":"7fbd9d","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581578814224856"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/165447047","repostId":1166489816,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":166706339,"gmtCreate":1624024281721,"gmtModify":1634023949983,"author":{"id":"3586511265760559","authorId":"3586511265760559","authorIdStr":"3586511265760559","name":"Pierroye","avatar":"https://static.tigerbbs.com/264cd7a6ef3b6658ac33143689e3ec09","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586511265760559"},"htmlText":"Great. Like and comment pls","listText":"Great. Like and comment pls","text":"Great. Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166706339","repostId":1166489816,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":166559832,"gmtCreate":1624019280326,"gmtModify":1634024052543,"author":{"id":"3564307384077743","authorId":"3564307384077743","authorIdStr":"3564307384077743","name":"LWayne","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3564307384077743"},"htmlText":"More pls","listText":"More pls","text":"More pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166559832","repostId":1166489816,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":166569633,"gmtCreate":1624018344522,"gmtModify":1634024067236,"author":{"id":"3585312804980408","authorId":"3585312804980408","authorIdStr":"3585312804980408","name":"LaiSB","avatar":"https://static.tigerbbs.com/02ab60e191d391b446c88630f4f1e822","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585312804980408"},"htmlText":"Soon will up","listText":"Soon will up","text":"Soon will up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166569633","repostId":1166489816,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":166507293,"gmtCreate":1624015737212,"gmtModify":1634024098422,"author":{"id":"3575853611921015","authorId":"3575853611921015","authorIdStr":"3575853611921015","name":"Jack1999","avatar":"https://static.tigerbbs.com/0741f2d7c37c8d3b8bcf1ba37f5f0cb9","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3575853611921015"},"htmlText":"Pls comment and like","listText":"Pls comment and like","text":"Pls comment and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/166507293","repostId":1166489816,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4869353,"gmtCreate":1624016297493,"gmtModify":1635310857864,"authorId":3578486314090660,"author":{"id":3578486314090660,"authorId":3578486314090660,"name":"Ljj96","avatar":"https://static.tigerbbs.com/b66d1d644a6f635459a0bec88bb23225","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":166507293,"type":1,"supId":0,"prevId":0,"content":"Me <u>too</u>","text":"Me <u>too</u>","html":"Me <u>too</u>"}],"langContent":"EN"},{"id":166508473,"gmtCreate":1624015394892,"gmtModify":1634024101772,"author":{"id":"3565081661382277","authorId":"3565081661382277","authorIdStr":"3565081661382277","name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3565081661382277"},"htmlText":"&nbsp;Nice","listText":"&nbsp;Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166508473","repostId":1166489816,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":119,"commentSize":46,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166489816"}